Clinical Trial

Immune Modulation With PRaG-1 Treatment

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 10, 2025 (before its estimated May 26, 2026 completion). Its status may not reflect the trial's current state.
Summary
The study is a single-center, prospective, single-arm, Phase II clinical trial. Eligible patients with advanced solid malignant tumors will sign the informed consent form and undergo screening for enrollment. After enrollment, patients will receive oral administration of "PRaG-1" twice daily (morning and evening) for a total of 10 days. Peripheral blood lymphocyte tests will be performed before treatment, on day 5 post-treatment, and at the conclusion of treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-25.
Trial Details
NCT Number NCT07002502
Lead Sponsor Second Affiliated Hospital of Soochow University
Conditions Cancer, Solid Cancer
Enrollment 19 participants
Start Date 2025-06-15
Primary Completion 2026-05-26 (estimated)
Study Completion 2026-06-26 (estimated)
Updated on ClinicalTrials.gov 2025-06-10